Lim S H, Spring K J, de Souza P, MacKenzie S, Bokey L
Medical Oncology Group, Ingham Institute for Applied Medical Research, Liverpool 2170, Australia; Department of Medical Oncology, Liverpool Hospital, Liverpool 2170, Australia; School of Medicine, University of New South Wales, Kensington 2052, Australia; Centre for Oncology Education and Research Translation (CONCERT), Liverpool 2170, Australia.
Medical Oncology Group, Ingham Institute for Applied Medical Research, Liverpool 2170, Australia; Centre for Oncology Education and Research Translation (CONCERT), Liverpool 2170, Australia; Liverpool Clinical School, University of Western Sydney, Liverpool 2170, Australia.
Eur J Surg Oncol. 2015 Mar;41(3):309-14. doi: 10.1016/j.ejso.2014.12.005. Epub 2014 Dec 30.
There is accumulating evidence for circulating tumour cells (CTCs) and circulating tumour nucleic acids (ctNAs) as prognostic and predictive biomarkers in colorectal cancer. Their role in the perioperative setting is evolving. These blood-borne biomarkers can potentially demonstrate tumour dissemination at time of colorectal cancer surgery and estimate the completeness of a surgical resection. CTCs and circulating ctNA levels at time of surgery, and persistent levels post-surgery, may correlate with poorer patient outcomes. These biomarkers can be utilised to refine surgical techniques to minimise tumour dissemination and determine the need for adjuvant therapy.
越来越多的证据表明，循环肿瘤细胞（CTCs）和循环肿瘤核酸（ctNAs）可作为结直肠癌的预后和预测生物标志物。它们在围手术期的作用正在不断演变。这些血源生物标志物有可能在结直肠癌手术时显示肿瘤播散情况，并评估手术切除的完整性。手术时的CTCs和循环ctNA水平以及术后的持续水平可能与患者较差的预后相关。这些生物标志物可用于改进手术技术，以尽量减少肿瘤播散，并确定辅助治疗的必要性。
